September 1st, 2021 MAPS Canada is pleased to announce the appointment of Scott Bernstein as our new Executive Director. A lawyer based in Vancouver, BC, Scott brings over 13 years’ experience in national and international drug policy reform. Prior to joining MAPS Canada, Scott served as Director of Policy for the Canadian Drug Policy Coalition, […]
Objective The Center for Psychedelic and Consciousness Research at Johns Hopkins Medical school in Baltimore conducted a randomized, controlled clinical trial to examine if one or two administrations of psilocybin, in addition to psychological support, could be an effective treatment for patients suffering from major depressive disorder (MDD). What is Major Depressive disorder? Major depressive
It is vital that we begin to recognize the urgency of identifying effective and accessible treatments for PTSD and other mental health issues. Based on the current lack of such treatments, this urgency may involve investigating some substances that had been previously deemed as “drugs of abuse” for the last half a century.